Abstract
AbstractIncorporation of technical risk in compound real options has been considered in Cassimon et al. (2011) concerning the valuation of multi-stage pharmaceutical R&D. There, the technical success probabilities at each development stage were assumed to be generated independently of each other. This assumption can be unrealistic in many applied problems, pharmaceutical R&D included. We present a valuation procedure dealing with dependent success probabilities and random development stage times. This greater flexibility allows a better description of the sequence of decision stages and results, which in turn, impact the value of the considered project. The theoretical results are illustrated through a numerical example that shows the implementation of the model to a pharmaceutical R&D problem.
Funder
Università degli Studi G. D’Annunzio Chieti Pescara
Publisher
Springer Science and Business Media LLC
Subject
General Economics, Econometrics and Finance,Finance
Reference26 articles.
1. Amram, M., Kulatilaka, N.: Real Options: Managing Strategic Investment in an Uncertain World. Boston: Harvard Business School Press (1999)
2. Barbu, V.S., Karagrigoriou, A.: Modeling and inference for multi-state systems. In: Lisnianski, A., Frenkel, I., Karagrigoriou, A. (eds.) Recent Advances in Multi-state Systems Reliability, pp. 59–70. Berlin: Springer (2018)
3. Borison, A.: Real options analysis: where are the emperor’s clothes? J Appl Corporate Finance 17, 17–31 (2005)
4. Brennan, M.J., Schwartz, E.S.: Evaluating natural resource investments. J Bus 58, 135–157 (1985)
5. Cassimon, D., De Backer, M., Engelen, P.J., Van Wouwe, M., Yordanov, V.: Incorporating technical risk in compound real option models to value a pharmaceutical R&D licensing opportunity. Res Policy 40, 1200–1216 (2011)
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献